GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Molecular Partners AG (XSWX:MOLN) » Definitions » EV-to-FCF

Molecular Partners AG (XSWX:MOLN) EV-to-FCF : 1.29 (As of May. 12, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Molecular Partners AG EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Molecular Partners AG's Enterprise Value is CHF-76.91 Mil. Molecular Partners AG's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was CHF-59.81 Mil. Therefore, Molecular Partners AG's EV-to-FCF for today is 1.29.

The historical rank and industry rank for Molecular Partners AG's EV-to-FCF or its related term are showing as below:

XSWX:MOLN' s EV-to-FCF Range Over the Past 10 Years
Min: -24.5   Med: -0.49   Max: 3.53
Current: 1.29

During the past 11 years, the highest EV-to-FCF of Molecular Partners AG was 3.53. The lowest was -24.50. And the median was -0.49.

XSWX:MOLN's EV-to-FCF is ranked better than
61.03% of 390 companies
in the Biotechnology industry
Industry Median: 6.365 vs XSWX:MOLN: 1.29

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-12), Molecular Partners AG's stock price is CHF3.235. Molecular Partners AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was CHF-1.890. Therefore, Molecular Partners AG's PE Ratio for today is At Loss.


Molecular Partners AG EV-to-FCF Historical Data

The historical data trend for Molecular Partners AG's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Molecular Partners AG EV-to-FCF Chart

Molecular Partners AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -93.65 -14.29 -4.86 -0.19 1.17

Molecular Partners AG Quarterly Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.19 0.81 0.57 1.30 1.17

Competitive Comparison of Molecular Partners AG's EV-to-FCF

For the Biotechnology subindustry, Molecular Partners AG's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Molecular Partners AG's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Molecular Partners AG's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Molecular Partners AG's EV-to-FCF falls into.



Molecular Partners AG EV-to-FCF Calculation

Molecular Partners AG's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=-76.906/-59.813
=1.29

Molecular Partners AG's current Enterprise Value is CHF-76.91 Mil.
Molecular Partners AG's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF-59.81 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Molecular Partners AG  (XSWX:MOLN) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Molecular Partners AG's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=3.235/-1.890
=At Loss

Molecular Partners AG's share price for today is CHF3.235.
Molecular Partners AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF-1.890.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Molecular Partners AG EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Molecular Partners AG's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Molecular Partners AG (XSWX:MOLN) Business Description

Traded in Other Exchanges
Address
Wagistrasse 14, Schlieren, Zurich, CHE, 8952
Molecular Partners AG is a clinical stage biopharmaceutical company. The company focuses on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Molecular Partners AG (XSWX:MOLN) Headlines

From GuruFocus

Molecular Partners Provides Updates at 41st Annual JPM Healthcare Conference

By Stock market mentor Stock market mentor 01-08-2023